Li Xuesong, Wang Bianhong, Liu Hao, Yu Zhuo
Department of Medical Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Front Immunol. 2025 Mar 5;16:1528198. doi: 10.3389/fimmu.2025.1528198. eCollection 2025.
Modality treatment including surgery, chemotherapy, radiation and immunotherapy was considered as standard strategy for tonsillar squamous cell carcinoma (TSCC). We reported a case of a 78-year-old man under severe underlying medical conditions who diagnosed with human papillomavirus (HPV)-positive and programmed death ligand 1 (PD-L1)-positive TSCC. He was administered camrelizumab combined with gemcitabine (GEM) for 8 cycles with partial response. Then, we gave him concurrent nanoparticle albumin-bound paclitaxel (nab-paclitaxel)-based chemoradiation. Eventually, this patient achieved complete response without severe adverse events. After a 12-month follow-up, he had no recurrence or metastasis.
包括手术、化疗、放疗和免疫治疗在内的综合治疗被认为是扁桃体鳞状细胞癌（TSCC）的标准治疗策略。我们报告了一例78岁患有严重基础疾病的男性患者，他被诊断为人乳头瘤病毒（HPV）阳性且程序性死亡配体1（PD-L1）阳性的TSCC。他接受了卡瑞利珠单抗联合吉西他滨（GEM）治疗8个周期，部分缓解。然后，我们给予他同步基于纳米白蛋白结合型紫杉醇（nab-紫杉醇）的放化疗。最终，该患者获得完全缓解且无严重不良事件。经过12个月的随访，他没有复发或转移。
